Medicaid Coverage of Methadone Maintenance and the Use of Opioid Agonist Therapy among Pregnant Women in Specialty Treatment

Marcus A. Bachhuber, Pooja K. Mehta, Laura J. Faherty, Brendan Saloner

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Opioid agonist therapy (OAT) is the standard of care for pregnant women with opioid use disorder (OUD). Medicaid coverage policies may strongly influence OAT use in this group. Objective: To examine the association between Medicaid coverage of methadone maintenance and planned use of OAT in the publicly funded treatment system. Research Design: Retrospective cross-sectional analysis of treatment admissions in 30 states extracted from the Treatment Episode Data Set (2013 and 2014). Subjects: Medicaid-insured pregnant women with OUD (n=3354 treatment admissions). Measures: The main outcome measure was planned use of OAT on admission. The main exposure was state Medicaid coverage of methadone maintenance. Using multivariable logistic regression models adjusting for sociodemographic, substance use, and treatment characteristics, we compared the probability of planned OAT use in states with Medicaid coverage of methadone maintenance versus states without coverage. Results: A total of 71% of pregnant women admitted to OUD treatment were 18-29 years old, 85% were white non-Hispanic, and 56% used heroin. Overall, 74% of admissions occurred in the 18 states with Medicaid coverage of methadone maintenance and 53% of admissions involved planned use of OAT. Compared with states without Medicaid coverage of methadone maintenance, admissions in states with coverage were significantly more likely to involve planned OAT use (adjusted difference: 32.9 percentage points, 95% confidence interval, 19.2-46.7). Conclusions: Including methadone maintenance in the Medicaid benefit is essential to increasing OAT among pregnant women with OUD and should be considered a key policy strategy to enhance outcomes for mothers and newborns.

Original languageEnglish (US)
Pages (from-to)985-990
Number of pages6
JournalMedical Care
Volume55
Issue number12
DOIs
StatePublished - Jan 1 2017

Fingerprint

Methadone
Medicaid
Opioid Analgesics
Pregnant Women
Therapeutics
Logistic Models
Heroin
Standard of Care
Research Design

Keywords

  • access to care
  • heroin dependence
  • insurance
  • medicaid
  • methadone maintenance
  • opioid substitution therapy
  • opioid use disorder
  • pregnancy

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Medicaid Coverage of Methadone Maintenance and the Use of Opioid Agonist Therapy among Pregnant Women in Specialty Treatment. / Bachhuber, Marcus A.; Mehta, Pooja K.; Faherty, Laura J.; Saloner, Brendan.

In: Medical Care, Vol. 55, No. 12, 01.01.2017, p. 985-990.

Research output: Contribution to journalArticle

Bachhuber, Marcus A. ; Mehta, Pooja K. ; Faherty, Laura J. ; Saloner, Brendan. / Medicaid Coverage of Methadone Maintenance and the Use of Opioid Agonist Therapy among Pregnant Women in Specialty Treatment. In: Medical Care. 2017 ; Vol. 55, No. 12. pp. 985-990.
@article{05b73767012a4201a7671991f91f89d3,
title = "Medicaid Coverage of Methadone Maintenance and the Use of Opioid Agonist Therapy among Pregnant Women in Specialty Treatment",
abstract = "Background: Opioid agonist therapy (OAT) is the standard of care for pregnant women with opioid use disorder (OUD). Medicaid coverage policies may strongly influence OAT use in this group. Objective: To examine the association between Medicaid coverage of methadone maintenance and planned use of OAT in the publicly funded treatment system. Research Design: Retrospective cross-sectional analysis of treatment admissions in 30 states extracted from the Treatment Episode Data Set (2013 and 2014). Subjects: Medicaid-insured pregnant women with OUD (n=3354 treatment admissions). Measures: The main outcome measure was planned use of OAT on admission. The main exposure was state Medicaid coverage of methadone maintenance. Using multivariable logistic regression models adjusting for sociodemographic, substance use, and treatment characteristics, we compared the probability of planned OAT use in states with Medicaid coverage of methadone maintenance versus states without coverage. Results: A total of 71{\%} of pregnant women admitted to OUD treatment were 18-29 years old, 85{\%} were white non-Hispanic, and 56{\%} used heroin. Overall, 74{\%} of admissions occurred in the 18 states with Medicaid coverage of methadone maintenance and 53{\%} of admissions involved planned use of OAT. Compared with states without Medicaid coverage of methadone maintenance, admissions in states with coverage were significantly more likely to involve planned OAT use (adjusted difference: 32.9 percentage points, 95{\%} confidence interval, 19.2-46.7). Conclusions: Including methadone maintenance in the Medicaid benefit is essential to increasing OAT among pregnant women with OUD and should be considered a key policy strategy to enhance outcomes for mothers and newborns.",
keywords = "access to care, heroin dependence, insurance, medicaid, methadone maintenance, opioid substitution therapy, opioid use disorder, pregnancy",
author = "Bachhuber, {Marcus A.} and Mehta, {Pooja K.} and Faherty, {Laura J.} and Brendan Saloner",
year = "2017",
month = "1",
day = "1",
doi = "10.1097/MLR.0000000000000803",
language = "English (US)",
volume = "55",
pages = "985--990",
journal = "Medical Care",
issn = "0025-7079",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Medicaid Coverage of Methadone Maintenance and the Use of Opioid Agonist Therapy among Pregnant Women in Specialty Treatment

AU - Bachhuber, Marcus A.

AU - Mehta, Pooja K.

AU - Faherty, Laura J.

AU - Saloner, Brendan

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: Opioid agonist therapy (OAT) is the standard of care for pregnant women with opioid use disorder (OUD). Medicaid coverage policies may strongly influence OAT use in this group. Objective: To examine the association between Medicaid coverage of methadone maintenance and planned use of OAT in the publicly funded treatment system. Research Design: Retrospective cross-sectional analysis of treatment admissions in 30 states extracted from the Treatment Episode Data Set (2013 and 2014). Subjects: Medicaid-insured pregnant women with OUD (n=3354 treatment admissions). Measures: The main outcome measure was planned use of OAT on admission. The main exposure was state Medicaid coverage of methadone maintenance. Using multivariable logistic regression models adjusting for sociodemographic, substance use, and treatment characteristics, we compared the probability of planned OAT use in states with Medicaid coverage of methadone maintenance versus states without coverage. Results: A total of 71% of pregnant women admitted to OUD treatment were 18-29 years old, 85% were white non-Hispanic, and 56% used heroin. Overall, 74% of admissions occurred in the 18 states with Medicaid coverage of methadone maintenance and 53% of admissions involved planned use of OAT. Compared with states without Medicaid coverage of methadone maintenance, admissions in states with coverage were significantly more likely to involve planned OAT use (adjusted difference: 32.9 percentage points, 95% confidence interval, 19.2-46.7). Conclusions: Including methadone maintenance in the Medicaid benefit is essential to increasing OAT among pregnant women with OUD and should be considered a key policy strategy to enhance outcomes for mothers and newborns.

AB - Background: Opioid agonist therapy (OAT) is the standard of care for pregnant women with opioid use disorder (OUD). Medicaid coverage policies may strongly influence OAT use in this group. Objective: To examine the association between Medicaid coverage of methadone maintenance and planned use of OAT in the publicly funded treatment system. Research Design: Retrospective cross-sectional analysis of treatment admissions in 30 states extracted from the Treatment Episode Data Set (2013 and 2014). Subjects: Medicaid-insured pregnant women with OUD (n=3354 treatment admissions). Measures: The main outcome measure was planned use of OAT on admission. The main exposure was state Medicaid coverage of methadone maintenance. Using multivariable logistic regression models adjusting for sociodemographic, substance use, and treatment characteristics, we compared the probability of planned OAT use in states with Medicaid coverage of methadone maintenance versus states without coverage. Results: A total of 71% of pregnant women admitted to OUD treatment were 18-29 years old, 85% were white non-Hispanic, and 56% used heroin. Overall, 74% of admissions occurred in the 18 states with Medicaid coverage of methadone maintenance and 53% of admissions involved planned use of OAT. Compared with states without Medicaid coverage of methadone maintenance, admissions in states with coverage were significantly more likely to involve planned OAT use (adjusted difference: 32.9 percentage points, 95% confidence interval, 19.2-46.7). Conclusions: Including methadone maintenance in the Medicaid benefit is essential to increasing OAT among pregnant women with OUD and should be considered a key policy strategy to enhance outcomes for mothers and newborns.

KW - access to care

KW - heroin dependence

KW - insurance

KW - medicaid

KW - methadone maintenance

KW - opioid substitution therapy

KW - opioid use disorder

KW - pregnancy

UR - http://www.scopus.com/inward/record.url?scp=85034840862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034840862&partnerID=8YFLogxK

U2 - 10.1097/MLR.0000000000000803

DO - 10.1097/MLR.0000000000000803

M3 - Article

C2 - 29135769

AN - SCOPUS:85034840862

VL - 55

SP - 985

EP - 990

JO - Medical Care

JF - Medical Care

SN - 0025-7079

IS - 12

ER -